Outcome postponement as a potential patient centred measure of therapeutic benefit: examples in cardiovascular medicine

References

• Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988;318:1728–1733.
   PubMed Web of Science ®Google Scholar
• Wright JC, Weinstein MC. Gains in life expectancy from medical interventions-standardizing data on outcomes. N Engl J Med. 1998;339:380–386.
   PubMed Web of Science ®Google Scholar
• Kristensen ML, Christensen PM, Hallas J. The effect of statins on average survival in randomised trials, an analysis of end point postponement. BMJ Open. 2015;5:e007118.
   PubMed Web of Science ®Google Scholar
• Christensen PM, Brosen K, Brixen K, et al. Randomized trial of laypersons’ perception of the benefit of osteoporosis therapy: number needed to treat versus postponement of hip fracture. Clin Ther. 2003;10:2575–2585.
   Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681.
   PubMed Web of Science ®Google Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, for the IMPROVE-IT Investigators, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–2397.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, FOURIER Steering Committee and Investigators, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–1722.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech A, et al. Rationale and design of the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk trial. Am Heart J. 2016;173:94–101.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Thuren T, et al. CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–1131.
   Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–1057.
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791–1800.
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Connolly SJ, Bosch J, et al. COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017;377:1319–1330.
   Google Scholar
• McMurray JJ, Packer M, Desai AS, PARADIGM-HF Investigators and Committees, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.
   PubMed Web of Science ®Google Scholar
• CONSENSUS Trial Study G. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429–1435.
   Web of Science ®Google Scholar
• Yusuf S, Pitt B, Davis CE, et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302.
   PubMed Web of Science ®Google Scholar
• Swedberg K, Komajda M, Böhm M, SHIFT Investigators, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376:875–885.
   PubMed Web of Science ®Google Scholar
• Leon MB, Smith CR, Mack M, PARTNER Trial Investigators, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597–1607.
   PubMed Web of Science ®Google Scholar
• Makkar RR, Fontana GP, Jilaihawi H, et al. PARTNER Trial Investigators. Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med. 2012;366:1696–1704.
   PubMed Web of Science ®Google Scholar
• Thomas KB. The consultation and the therapeutic illusion. Br Med J. 1978;1:1327–1328.
   Google Scholar
• Hoffmann TC, Del Mar C. Clinicians’ expectations of the benefits and harms of treatments, screening, and tests: a systematic review. JAMA Int Med. 2017;177:407–419.
   PubMed Web of Science ®Google Scholar
• Ennezat PV, Vannesson C, Bouabdallaoui N, et al. Imagine how many lives you save: angiotensin-converting enzyme inhibition for atherosclerotic vascular disease in the present era of risk reduction. Expert Opin Pharmacother. 2011;12:883–897.
   PubMed Web of Science ®Google Scholar
• Bassler D, Briel M, Montori VM, et al. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA. 2010;303:1180–1187.
   PubMed Web of Science ®Google Scholar
• McQueen MJ, Hawken S, Wang X, INTERHEART study investigators, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008;372:224–233.
   PubMed Web of Science ®Google Scholar
• Guerbaai RA, Mahata I, Maréchaux S, et al. Is ticagrelor worth its high cost and side-effects? Acta Cardiol. 2018. DOI:10.1080/00015385.2018.1469371
   Web of Science ®Google Scholar
• Pilgrim T, Windecker S. Antiplatelet therapy for secondary prevention of coronary artery disease. Heart. 2014;100:1750–1756.
   Web of Science ®Google Scholar
• Swedberg K, Kjekshus J, Snapinn S. Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I. Eur Heart J. 1999;20:136–139.
   PubMed Web of Science ®Google Scholar
• Townend JN, Littler WA. Angiotensin converting enzyme inhibitors in heart failure: how good are they? Br Heart J. 1993;69:373–375.
   Google Scholar
• Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–717.
   PubMed Web of Science ®Google Scholar
• Lechat P, Packer M, Chalon S, et al. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation. 1998;98:1184–1191.
   PubMed Web of Science ®Google Scholar
• The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9–13.
   PubMed Web of Science ®Google Scholar
• Cleland JG, Daubert JC, Erdmann E, et al. Cardiac Resynchronization-Heart Failure (CARE-HF) study investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–1549.
   PubMed Web of Science ®Google Scholar
• Komajda M, Follath F, Swedberg K, et al. The euroheart failure survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J. 2003;24:464–474.
   PubMed Web of Science ®Google Scholar
• Ennezat PV, Cosgrove S, Maréchaux S, et al. Limited role and benefit of ivabradine in the treatment of angina and heart failure with reduced ejection fraction. Acta Cardiol. 2017;72(6):664–668.
   Web of Science ®Google Scholar
• Carabello BA. Introduction to aortic stenosis. Circ Res. 2013;113:179–185.
   PubMed Web of Science ®Google Scholar
• Gilard M, Eltchaninoff H, Donzeau-Gouge P, FRANCE 2 Investigators, et al. Late outcomes of transcatheter aortic valve replacement in high-risk patients: the FRANCE-2 registry. J Am Coll Cardiol. 2016;68:1637–1647.
   PubMed Web of Science ®Google Scholar
• Trinquart L, Jacot J, Conner SC, et al. Comparison of treatment effects measured by the hazard ratio and by the ratio of restricted mean survival times in oncology randomized controlled trials. J Clin Oncol. 2016;34:1813–1819.
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet. 2011;378:2013–2020.
   PubMed Web of Science ®Google Scholar
• Ennezat PV, Cosgrove S, Bouvaist H, et al. From evidence-based medicine to personalized medicine, with particular emphasis on drug-safety monitoring. Arch Cardiovasc Dis. 2017;110:413–419.
   Web of Science ®Google Scholar
• Rentería E, Jha P, Forman D, et al. The impact of cigarette smoking on life expectancy between 1980 and 2010: a global perspective. Tob Control. 2016;25:551–557.
   PubMed Web of Science ®Google Scholar
• Long MW, Gortmaker SL, Ward ZJ, et al. Cost effectiveness of a sugar-sweetened beverage excise tax in the U.S. Am J Prev Med. 2015;49:112–123.
   PubMed Web of Science ®Google Scholar
• Moore SC, Patel AV, Matthews CE, et al. Leisure time physical activity of moderate to vigorous intensity and mortality: a large pooled cohort analysis. PLoS Med. 2012;9:e1001335.
   PubMed Web of Science ®Google Scholar